Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:14 PM
Ignite Modification Date: 2025-12-24 @ 10:14 PM
NCT ID: NCT01288235
Eligibility Criteria: Inclusion Criteria: * Biopsy proven low grade glioma or astrocytoma, ependymoma, craniopharyngioma, meningioma, neurocytoma, medulloblastoma or gangliogliomas or other rare tumor requiring tumor bed or tumor irradiation. Patients with a presumed diagnosis of optic glioma or gliomas based on imaging and clinical characteristics will also be allowed on this trial. * Patients with biopsy proven high grade glioma (excluding GBM) and a gross total resection and patients with non-disseminated atypical teratoid rhabdoid (ATRT) may also be included. * Pathologic diagnosis must be based on pathology or pathology review by Department of Pathology at MGH or another DF/HCC institution. * Age between 1-25 years. * Life expectancy of greater than 1 year. * ECOG Performance Status 0, 1, 2 or 3 or Lansky performance status 30 or greater. * Girls and women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Exclusion Criteria: * Participants who have had radiotherapy to the site to be treated. * Participants with known spinal or distant metastases. Patients with ependymoma, medulloblastoma or germinoma must have metastatic workup including spine MRI to rule out metastases. * Uncontrolled intercurrent illness that would limit compliance with study requirements. * Pregnant or breastfeeding women. * Patients who cannot participate in contributing to the neurocognitive outcomes due to severe neurologic impairment or language barrier (ie not English or Spanish speaking) will be excluded from this study.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 1 Year
Maximum Age: 25 Years
Study: NCT01288235
Study Brief:
Protocol Section: NCT01288235